Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
August 08, 2022 07:00 ET
|
Ocuphire Pharma
Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022 H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022, including a Fireside Panel with OCUP “Front of...
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
August 03, 2022 08:00 ET
|
Ocuphire Pharma
Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication Growing Patent Estate Eligible for FDA Orange Book Listing On Track to File NDA for Nyxol in First Indication...
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
July 07, 2022 08:00 ET
|
Ocuphire Pharma
Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking Paper Highlighting Data from Two Phase 3...
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
June 29, 2022 09:00 ET
|
Ocuphire Pharma
Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication Highlights the Critical Role of Inflammation...
Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting
June 08, 2022 08:00 ET
|
Ocuphire Pharma
Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks Topline Results with First-in-Class Non-Invasive Retinal Candidate APX3330 Expected in...
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
May 19, 2022 07:00 ET
|
Ocuphire Pharma
Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial...
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
May 13, 2022 08:00 ET
|
Ocuphire Pharma
Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in First Quarter NDA Filing on Track for Late...
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
May 11, 2022 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
April 28, 2022 07:00 ET
|
Ocuphire Pharma
Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials ...
Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022
April 26, 2022 09:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., April 26, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...